Early proinflammatory cytokines and C-reactive protein trends as predictors of outcome in invasive aspergillosis

Journal of Infectious Diseases

Volumn 202, Issue 9, 2010, Pages 1454-1462

  Chai, Louis Y A ^a,c   Netea, Mihai G ^a   Teerenstra, Steven ^a   Earnest, Arul ^d   Vonk, Alieke G ^b   Schlamm, Haran T ^h   Herbrecht, Raoul ^f,g   Troke, Peter F ^e   Kullberg, Bart Jan ^a,g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d TAN TOCK SENG HOSPITAL   (Singapore)

^e Tan Tock Seng Hospital ^*  (United Kingdom)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g EORTC DATA CENTER   (Belgium)

^h Pf Izer Global Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; ASPERGILLOSIS; BLOOD; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; C-REACTIVE PROTEIN; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 77958092037     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/656527     Document Type: Article

References (28)

1. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48:265-273.
2. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250-260.
3. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253-259. (Pubitemid 32063503)
4. Chai LY, Netea MG, Vonk AG, Kullberg B-J. Fungal strategies for overcoming host innate immune response. Med Mycol 2009; 47:227-236.
5. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4:1-23.
6. Netea MG, Brown GD, Kullberg B-J, Gow NA. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008; 6:67-78.
7. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006; 2:619-626
8. Balloy V, Chignard M. The innate immune response to Aspergillus fumigatus. Microbes Infect 2009; 11:919-927.
9. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415. (Pubitemid 34851833)
10. Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41:1448-1452. (Pubitemid 41579987)
11. Lehrnbecher T, Venzon D, de Haas M, Chanock SJ, Kühl J. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc γ receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis 1999; 29:414-419. (Pubitemid 29380209)
12. de Bont ES, Vellenga E, Swaanenburg JC, Fidler V, Visser-van Brummen PJ, Kamps WA. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol 1999; 107:375-380. (Pubitemid 29530226)
13. Diepold M, Noellke P, Duffner U, Kontny U, Berner R. Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis 2008; 8:28. (Pubitemid 351541233)
14. Prat C, Sancho JM, Dominguez J, et al. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008; 49:1752-1761.
15. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-217. (Pubitemid 38971491)
16. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14. (Pubitemid 33152659)
17. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-1821.
18. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 47:674-683.
19. Webster NR, Galley HF. Immunomodulation in the critically ill. Br J Anaesth 2009; 103:70-81.
20. Castellheim A, Brekke OL, Espevik T, Harboe M, Mollnes TE. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 2009; 69:479-491.
21. Zelante T, Bozza S, De Luca A, et al. Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol 2009; 47(Suppl 1):S162-S169.
22. Schmit X, Vincent JL. The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with sepsis. Infection 2008; 36:213-219.
23. Min CK, Lee WY, Min DJ, et al. The kinetics of circulating cytokines including IL-6, TNF-α, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28:935-940.
24. Roilides E, Sein T, Roden M, Schaufele RL, Walsh TJ. Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis. J Infect Dis 2001; 183:518-520. (Pubitemid 32105614)
25. Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100:4521-4528.
26. +-T-cell responses to live and heat-inactivated Aspergillus fumigatus conidia. Infect Immun 2005; 73:7170-7179.
27. + T cell priming during respiratory fungal infection. Immunity 2006; 25:665-675.
28. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci 2004; 1024:138-146.